Document Detail


Potential side effects of renin inhibitors--mechanisms based on comparison with other renin-angiotensin blockers.
MedLine Citation:
PMID:  16907653     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Angiotensin (Ang) II plays important roles in the development of hypertension and cardiovascular and renal injury. Pharmaceutical approaches to block its activity led to the development of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Numerous trials have documented their efficacy in controlling blood pressure, minimising left ventricular remodelling, preventing progression to heart failure, ameliorating proteinuria and retarding renal disease progression. Although they are considered safe in general, there remain concerns about the potential for adverse events in certain target populations. Recently, several novel, low molecular weight renin inhibitors without the extended peptide-like backbone of previous renin inhibitors were developed with favourable pharmacokinetic properties. They have been shown to successfully reduce Ang II levels in normal volunteers and to lower blood pressure in patients with mild-to-moderate hypertension. In this review, the authors summarise current knowledge about these renin inhibitors.
Authors:
Huifang Cheng; Raymond C Harris
Related Documents :
991543 - Neural factors contributing to renin release during reduction in renal perfusion pressu...
6400363 - Neuropeptides in cardiovascular control.
494223 - Hemodynamic changes after experimental reduction of the left atrium.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on drug safety     Volume:  5     ISSN:  1744-764X     ISO Abbreviation:  Expert Opin Drug Saf     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-08-15     Completed Date:  2006-08-23     Revised Date:  2008-04-14    
Medline Journal Info:
Nlm Unique ID:  101163027     Medline TA:  Expert Opin Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  631-41     Citation Subset:  IM    
Affiliation:
George M. O'Brien Kidney and Urologic Diseases Center and Division of Nephrology, Vanderbilt University School of Medicineand Nashville Veterans Affairs Hospital, Nashville, TN 37232, USA. huifang.cheng@vanderbilt.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abnormalities, Drug-Induced / etiology
Amides
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  therapeutic use*
Animals
Clinical Trials as Topic
Fumarates / adverse effects,  therapeutic use
Humans
Hyperkalemia / chemically induced*
Hypertension / drug therapy*
Hypotension / chemically induced*
Inappropriate ADH Syndrome / chemically induced
Male
Mice
Receptors, Angiotensin / antagonists & inhibitors*
Renin / antagonists & inhibitors*,  physiology
Chemical
Reg. No./Substance:
0/Amides; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Fumarates; 0/Receptors, Angiotensin; 0/aliskiren; EC 3.4.23.15/Renin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cardiac dysfunction associated with trastuzumab.
Next Document:  Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it.